RJA
IBIO icon

Raymond James & Associates’s iBio IBIO Stock Holding History

Raymond James & Associates’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22
Closed -$17K – 4139
2021
Q1 		$17K Hold
22
– – ﹤0.01% 3927
2020
Q4 		$12K Hold
22
– – ﹤0.01% 3724
2020
Q3 		$22K Buy
+22
New +$31.9K ﹤0.01% 3504
2017
Q1 		– Sell
-10
Closed -$20K – 3345
2016
Q4 		$20K Hold
10
– – ﹤0.01% 3151
2016
Q3 		$28K Hold
10
– – ﹤0.01% 3113
2016
Q2 		$36K Hold
10
– – ﹤0.01% 2902
2016
Q1 		$28K Buy
+10
New +$28.7K ﹤0.01% 2833

Other funds holding IBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Raymond James & Associates's IBIO Position: Q2 2021 in Review

Raymond James & Associates sold out of iBio (IBIO) in Q2 2021, closing a stake of 22 shares — an estimated $17K sold.

Raymond James & Associates first reported a position in IBIO in Q1 2016 and held it in 7 quarters. The position peaked at $36K in Q2 2016. 83 funds tracked by Wall St. Rank hold IBIO as of Q2 2021.

  • Raymond James & Associates reported no remaining iBio position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 22 iBio shares in Q2 2021, an estimated $17K.
  • Raymond James & Associates first reported a position in iBio in Q1 2016 and held it in 7 quarters.
  • Raymond James & Associates's iBio position peaked at $36K in Q2 2016.
  • 83 funds tracked by Wall St. Rank held iBio as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.